Buy, hold, sell: Nick Scali, Nyrada, Wesfarmers shares

S&P/ASX 200 Index (ASX: XJO) shares fell 0.2% to 8,633.2 points yesterday.

Let’s check out what these experts think of three ASX shares in the retail and healthcare sectors.

Nick Scali Ltd (ASX: NCK)

The Nick Scali share price closed at $15.05, down 1.1% yesterday and down 36% in the calendar year to date (YTD). 

Morgans commenced coverage on this ASX 200 retail share with a buy rating this week.

The broker said it was looking through weak near-term consumer sentiment, and that the current share price is attractive.

Morgans described Nick Scali as a “high-quality retailer with a long track record”.

In a new note, the broker explained its buy recommendation:

Nick Scali has delivered long-term EPS growth through disciplined store rollout, LFL growth, best-in-class margins, and operating leverage. Strong cash generation and balance sheet.

Structural negative working capital supports high cash conversion, while the low capital intensity of new store rollouts leaves ample cash flow for dividends and property purchases and/or growth ventures.

Store rollout optionality. Further Plush and Nick Scali rollout in ANZ and the Nick Scali rollout opportunity in the UK provide an attractive growth leg.

Morgans has a 12-month target of $17.84, which suggests almost 20% upside ahead.

Nyrada Inc (ASX: NYR)

The Nyrada share price finished at 45 cents, down 8.2% yesterday and down 62% YTD. 

Nyrada is a biotech developing novel therapies for cardiovascular, neurological, and cancer-related diseases.

On The Bull this week, Tony Locantro from Alto Capital put a hold rating on this ASX biotech share.

Locantro commented: 

Recent announcements highlighted progress in the Phase IIa PROTECT-MI trial for its lead drug candidate Xolatryp, along with encouraging pre-clinical oncology data and additional patent protection.

These developments continue to strengthen confidence in the broader platform and its commercial potential.

However, the company remains at a clinical development stage, with key efficacy and regulatory milestones still ahead. While the long term opportunity remains attractive, the current risk profile supports a hold recommendation pending further clinical validation.

Wesfarmers Ltd (ASX: WES) 

The Wesfarmers share price closed at $84.31 on Thursday, up 1.1% for the day and up 3% YTD. 

Wesfarmers held its 2026 Strategy Briefing Day on Wednesday.

The diversified conglomerate highlighted its growth and productivity plans, its portfolio of high-quality businesses, and its strong balance sheet, which provides the potential to invest.

Managing Director Rob Scott said Wesfarmers’ primary objective remained satisfactory returns for shareholders.

Scott pointed out that Wesfarmers shares had delivered an average annual return of 15.8% over 10 years.

This compares to a 9.2% average annual return from the All Ordinaries Accumulation Index.

After the event, Citi reiterated its sell call on the ASX 200’s biggest consumer discretionary share.

The broker has a price target of $69 on Wesfarmers shares.

This indicates a potential near-20% downside ahead.

The post Buy, hold, sell: Nick Scali, Nyrada, Wesfarmers shares appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• Are Wesfarmers shares a buy, sell or hold after this week’s update?
• Down 40%+! 2 cheap ASX shares I’d buy before the recovery becomes obvious
• Here are the top 10 ASX 200 shares today
• I love Wesfarmers shares. Here’s why I’m not buying more

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Nick Scali and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.